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The Symposium on Innovative Polymers 
for Controlled Delivery (SIPCD), which is 
held every 2 years in Suzhou, China, aims 
to bring together leading scientists, entre-
preneurs and prominent young research-
ers at the forefront of the biomedical 
polymer and nanomedicine fields, cover-
ing stimuli-responsive medical polymers, 
tumor-targeting drug release systems, con-
trolled gene transfer approaches, emerging 
diagnostic technologies, advanced tissue 
engineering and regenerative medicine. 
This series of symposia, first launched in 
September 2010 in reponse to the rapid 
technological advances in innovative poly-
mers and controlled delivery systems, has 
already been established as a high-level 
forum. The symposium is organized in 
one single session, thus offering partici-
pants the possibility to be present at all 
invited lectures, with ample opportunities 
to participate in lively discussions about 
the most recent developments, as well as 
challenges in controlled delivery.
The second SIPCD (SIPCD 2012) 
was held in September 2012 and had a 
particular focus on cutting-edge nano-
medicine. In addition to invited lectures 
by well-known scientists, including edi-
tors and associate editors of over ten 
prestigious journals, SIPCD 2012 also 
hosted an intriguing panel discussion on 
“What is the future of nanomedicine?”, 
as well as a tour of Suzhou BioBay – a 
top biomedical park in Suzhou, China. 
It is interesting to note that SIPCD 2012 
welcomed 418 delegates from 138 institu-
tions and companies from 18 countries, 
and accepted 252 poster presentations 
from more than 300 submissions follow-
ing a strict peer-review process. Notably, 
the six best poster presentations were 
granted prestigious Biomacromolecules 
Poster Awards (American Chemical 
Society) by Harm-Anton Klok, associ-
ate editor of Biomacromolecules. As in the 
first symposium in 2010 [1], a high-quality 
special issue that contains contributions 
made exclusively by the invited speakers 
of SIPCD 2012 will be published in the 
Journal of Controlled Release. It should also 
be noted that all poster abstracts presented 
at SIPCD 2012 will be published online in 
a special issue of the Journal of Controlled 
Release.
In recent years, there has been rapid prog-
ress in basic research, as well as in the clini-
cal development of polymeric systems for 
targeted and controlled delivery of potent 
chemotherapeutics, biopharma ceutics 
and diagnostic imaging agents. Kazunori 
Kataoka (University of Tokyo, Japan) 
opened the symposium with a lecture 
about his pioneer work on micelles based 
on poly(ethylene glycol)-b-poly(amino 
acids) block copolymers for anticancer 
drug and siRNA delivery. Notably, several 
micellar anticancer drug formulations have 
already been in clinical trials worldwide, 
including Japan, Taiwan, Singapore, the 
UK, France and USA [2]. Kataoka has 
demonstrated that dichloro(1,2–diami-
nocyclohexane)platinum(II)-loaded pH-
responding micelles are effective for the 
treatment of intractable pancreatic can-
cer. Si-Shen Feng (National University 
of Singapore, Singapore) developed pacli-
taxel and docetaxel formulations based 
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Recent developments in polymer-based controlled delivery systems have made a significant clinical impact. The 
second Symposium on Innovative Polymers for Controlled Delivery (SIPCD) was held in Suzhou, China to address 
the key challenges and provide up-to-date progress and future perspectives in the innovation of polymer-based 
therapeutics. At SIPCD, a stimulating panel discussion was introduced for the first time on “What is the future 
of nanomedicine?” This report highlights the most recent research and developments in biomedical polymers 
and nanomedicine made by 29 invited scientists from around the world, as well as important issues regarding 
clinical advancements of nanomedicine conferred during the panel discussion.
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on d-a-tocopherol poly(ethylene gly-
col) 1000 succinate emulsified biodegrad-
able poly(lactic-co-glycolic acid) (PLGA) 
nanoparticles that have shown improved 
therapeutic effects and better safety as 
compared with Taxol® (Bristol-Myers 
Squibb, NY, USA) and Taxotere® (Sanofi-
Aventis, Paris, France) in Sprague Dawley® 
rats (Charles River, MA, USA). Rainer 
Haag (Freie Universität Berlin, Germany) 
developed multi functional nano- and mic-
roparticles based on dendritic polyglycer-
ols for different biomedical applications, 
ranging from protein-resistant coatings, 
DNA transfection, anticoagulation and 
anti-inflammation to single cell entrap-
ment. Youqing Shen (Zhejiang University, 
China) emphasized that capability, excipi-
ent ability and scale-up ability are the 
three elements critical for translational 
nanomedicine. Stefaan de Smedt (Ghent 
University, Belgium) described new con-
cepts and characterization methods includ-
ing fluorescence single-particle tracking 
microscopy and fluorescence correlation 
spectroscopy for advanced drug delivery 
studies.
Biotherapeutics, such as proteins, pep-
tides and oligonucleotide drugs, exhibit 
several unique features, such as great thera-
peutic activity, high specificity and low tox-
icity over chemotherapeutics. Their clini-
cal applications, however, are challenged 
by the absence of an appropriate controlled 
release system. Jackie Y Ying (Institute of 
Bioengineering and Nanotechnology, 
Singapore) discussed the development of 
polymeric nanoparticles for on-demand 
glucose-sensitive release of insulin; apa-
tite-polymer nanocomposite particles for 
zero-order release of protein therapeutics, 
such as bone morphogenetic proteins; and 
nanocomposite materials for theranostic 
applications and combination therapy. 
Hsing-Wen Sung (National Tsing Hua 
University, Taiwan) developed functional 
nanoparticles based on chitosan and poly(g-
glutamic acid)-ethylene glycol tetraacetic 
acid conjugate for enhanced absorption 
and protease inhibition in oral protein 
delivery. Johan FJ Engbersen (University 
of Twente, Enschede, The Netherlands), 
taking advantage of the reversible nature 
of boronate esters with diols and the 
enhanced cellular interactions of boronic 
acids, designed boronic acid-functionalized 
and bioreducible poly(amido amine)s for 
glucose-responsive insulin release and 
efficient gene transfection. Frank Caruso 
(University of Melbourne, Australia) dis-
cussed tailor-making of functional micro- 
and nano-sized capsules via sequential 
polymer assembly. The application of 
polymeric capsules for the encapsulation 
and release of oligonucleotides and pep-
tides to stimulate immune responses was 
highlighted.
The development of stimuli-responsive, 
particularly pH- and redox-responsive, 
nanocarriers for improved intracellular 
drug release and, therefore, therapeutic 
efficacy has been a focus of recent research. 
Fenghua Meng (Soochow University, 
Suzhou, China) designed several novel 
types of bio-responsive polymersomes, 
such as endosomal pH-sensitive degrad-
able chimeric polymersomes and pH/redox 
dual-responsive polymersomes, for efficient 
intracellular anticancer drug and protein 
release. Xi Zhang (Tsinghua University, 
Beijing, China) delivered a lecture on 
stimuli-responsive nanoparticles, based on 
amphiphilic selenium-containing polymers 
that respond to reduction and oxidation, as 
well as g-radiation. Deyue Yan (Shanghai 
Jiaotong University, Shanghai, China) 
developed multifunctional redox-respon-
sive nanocarriers from hyperbranched 
polyphosphates containing multiple reduc-
ible disulfide or diselenide bonds for intra-
cellular release of anti cancer drugs. Doo 
Sung Lee (Sungkyunkwan University, 
Seoul, Korea) designed various stimuli-
responsive micelles and hydrogels based on 
block copolymers of poly(ethylene glycol) 
and poly(b-aminoester)s for controlled 
release of anticancer drugs, imaging agents 
and/or proteins in vitro and in vivo. 
DNA, proteins and polypeptides have 
recently been developed as emerging 
materials for nanomedicine. Dan Luo 
(Cornell University, NY, USA) presented 
his work on DNA-based nanomaterials, 
including Y-shaped DNA, dendrimer-
like DNA, DNA nanobarcodes, DNA 
hydrogels, DNA liposomes and DNA 
organized nanoparticles, some of which 
have been investigated for point-of-care 
diagnostics and intracellular protein 
release. Timothy J Deming (University 
of California Los Angeles, CA, USA) 
addressed the novel synthesis of functional 
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polypeptide materials, polypeptide vesicles 
for drug delivery, as well as polypep-
tide hydrogels for CNS therapies. Xuesi 
Chen (Changchun Institute of Applied 
Chemistry, China) designed several new 
types of multi responsive polypeptide nano-
gels for efficient anticancer drug delivery. 
Ashutosh Chilkoti (Duke University, 
NC, USA) discussed the development of 
thermo sensitive elastin-like polypeptide 
nanoparticles for systemic anticancer 
drug delivery, as well as novel protease-
operated depots for local, sustained and 
tunable peptide drug release for the treat-
ment of Type II diabetes. Yong-Hee Kim 
(Hanyang University, Seoul, Korea) devel-
oped recombinant metallothionein fusion 
proteins as protective therapeutic agents 
against gluco lipotoxicity, hyperglycemia 
and hypoxia. Sébastien Lecommandoux 
(Université de Bordeaux, Talence, France) 
gave a lecture on the design of smart poly-
mersomes from glycoprotein-mimicking 
polypeptide–polysaccharide copolymers 
for targeted tumor therapy and the novel 
preparation of compartmentalized poly-
mersomes with an internal ‘gelly’ cavity. 
Harm-Anton Klok (Ecole Polytechnique 
Fédérale de Lausanne, Switzerland) 
designed peptide-synthetic polymer con-
jugates for effective binding and release of 
cargo, increased stability of HIV fusion 
inhibitors and/or increased activity of HIV 
entry inhibitors.
The success of gene therapy is critically 
dependent on the development of safe, 
efficient and viable gene delivery vehicles. 
Chae-Ok Yun (Hanyang University) pre-
sented versatile modification strategies 
of adenovirus with polymers and nano-
materials, such as poly(ethylene glycol), 
chitosan and arginine-grafted bioreduc-
ible polymer, to improve the antitumor 
efficacy, specificity and safety of systemic 
adenovirus-mediated cancer gene therapy. 
To address the high toxicity, low stabil-
ity and low specificity of cationic poly-
mer-based gene delivery systems, Wim 
E Hennink (Utrecht University, The 
Netherlands) developed novel decation-
ized disulfide-crosslinked polyplexes for 
nontoxic and eff icient redox-triggered 
intracellular gene delivery. David W 
Grainger (University of Utah, UT, USA) 
discussed the development of local siRNA 
and antibody delivery approaches from 
implant devices to bypass systemic siRNA 
dosing, targeting, stability and bioavail-
ability problems in device-associated 
fibrosis and osteoporosis. 
In addition to nanomedicine, novel 
medical materials, such as hydrogels and 
shape-memory polymers for controlled 
drug release and cell sheets for 3D tis-
sue and organ reconstruction, were also 
addressed. Phillip B Messersmith (North 
Western University, IL, USA) developed 
in situ-forming polymer hydrogels using 
the native chemical ligation method 
for drug delivery, medical sealing and 
wound healing applications. Jiandong 
Ding (Fudan University, Shanghai, 
China) discovered that the anticancer 
activity of camptothecin family drugs 
is significantly enhanced upon loading 
into PLGA–poly(ethylene glycol)–PLGA 
hydrogels. Gordon Wallace (University of 
Wollongong, Australia) communicated 
the combination of medical bionics with 
controlled local drug or NGF delivery to 
improve the electrode–cellular interface 
and, therefore, the performance of bionic 
devices. Diane J Burgess (University 
of Connecticut, CT, USA) developed 
long-term implantable glucose sensors by 
employing dexamethasone-loaded PLGA 
microsphere/polyvinyl alcohol hydro-
gel composites as outer sensor coatings. 
Andreas Lendlein (Helmholz-Zentrum 
Geesthacht, Germany) developed novel 
multifunctional drug delivery systems 
based on stimuli-sensitive shape-memory 
polymers, in which drug release profiles 
can be controlled by polymer degrada-
tion rate and drug loading technique. 
Teruo Okano (Tokyo Women’s Medical 
University, Japan) communicated the lat-
est development of 3D tissue and organ 
reconstruction by layered cell sheets. 
Human clinical studies have been initiated 
for cell sheet engineering therapy for the 
treatment of cornea epithelium-deficient 
disease and cardiomyopathy.
Finally, the panel discussion on “What 
is the future of nanomedicine?” was led by 
Grainger, Frank Caruso, Si-Shen Feng and 
Hennink. Grainger made an introductory 
speech about the current status of nano-
medicine development. It was noted that 
nanomedicines such as Doxil® (Ben Venue 
Laboratories, OH, USA), Abraxane® 
(Celgene, NJ, USA) and PEG-Intron® 
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(Schering-Plough, NJ, USA) have already 
been applied in the clinic. These nano-
particle systems are either systemically 
administered or intended to have signifi-
cant systemic bioavailability. It has to be 
realized, however, that many challenges 
still exist before nanomedicine will become 
routine and reliable. As a community, we 
should avoid over-expectations, hype and 
hyperbole that might affect the credibility 
of nanomedicine as a field. It is important 
to properly convey what nanomedicine can 
do and its limitations. The targetability of 
nanomedicine is questionable given that 
typically only approximately 5% or less of 
the injected dose accumulates in tumors 
of mice. Consequently, inefficient intra-
tumoral penetration of nanomedicines due 
to their submicron sizes and affinity for 
the tumor cells in the peripheral region, 
as well as stiff tumor extracellular matrix 
and high interstitial fluid pressure confin-
ing therapeutic effects to the periphery of 
the tumor mass close to the vasculature, 
has been recognized as a significant bar-
rier for effective tumor therapy. The intra-
tumoral penetration of nanomedicines can 
be enhanced by using tumor-penetrating 
peptides such as iRGD, pharmacological 
treatments of tumors (collagenase and the 
hormone relaxin) and with the application 
of ultrasound. It should further be noted 
that there is a lack of proper animal mod-
els. The results obtained from mice are dif-
ficult to translate directly into humans. As 
a matter of fact, the clinical data indicated 
that the enhanced permeability and reten-
tion effect, if it exists, is not as obvious 
as that observed for mice, probably due to 
much slower tumor growth and relatively 
smaller tumor volumes in humans. Finally, 
nanomedicines also encounter manufac-
turing issues, such as large-scale produc-
tion, reproducibility and quality control. 
In this panel discussion, the most impor-
tant issues related to nanomedicines were 
addressed. It is generally accepted that 
nanomedicines will play a significant role 
in future medicines. In addition to paren-
tal delivery, nanomedicines also show 
promise for oral administration.
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